Categories: Wire Stories

OliX Pharmaceuticals to Participate in BIO-Europe Spring®

SUWON, South Korea–(BUSINESS WIRE)–#BIOEuropeSpring—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the Company’s management will participate in one-on-one partnering meetings at BIO-Europe Spring. The event is being held digitally from March 28-31, 2022.

Dr. Sun Woo Hong, Head of External Collaboration, and Dr. June Park, Principal Scientist, will meet industry experts to discuss platform-based early discovery collaborations as well as global licensing options for pipeline programs, including OLX101A for hypertrophic scars (Phase 2), OLX703A for hepatitis B virus, and OLX702A for nonalcoholic steatohepatitis.

This year, BIO-Europe Spring, Europe’s largest springtime biopharma industry gathering, will serve the global biotechnology industry, including more than 1000 companies from 45 countries. To schedule a virtual meeting, please visit the BIO-Europe Spring® platform at https://informaconnect.com/bioeurope-spring/partnering/.

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Learn more: https://www.olixpharma.com/eng

Contacts

Kelly Kim

OliX Pharmaceuticals

+82-2-3489-4800

ccnc@olixpharma.com

 

Alex

Alex is a writer and digital content enthusiast who enjoys covering technology, current trends, useful tips, and topics that matter to everyday readers. With a focus on clear, informative, and easy-to-understand content, Alex aims to provide readers with practical insights and interesting perspectives across a wide range of subjects.

Recent Posts

Sri Lanka vs Pakistan ODI Tri-Series 2026 Final: Match Overview and Key Insights

Key takeaways:Pakistan and Sri Lanka compete in the final match of the 2026 ODI Tri-Series…

15 minutes ago

Sri Lanka vs Oman Match Recap: Shanaka and Rathnayake Lead Victory in T20WC 2026

Key takeaways:Sri Lanka defeated Oman in the 16th Match of Group B during the T20…

46 minutes ago

Sanjay Gupta Passes Away: Kaante and Zinda Director Dies After Fall

Key takeaways:Director Sanjay Gupta, known for films like Kaante and Zinda, died following a fall.Media…

1 hour ago

Hong Kong vs Pakistan: Hong Kong Sixes 2026 Tournament Highlights and Group C Analysis

Key takeaways:Pakistan secured a four-wicket victory over rival India in Group C of the Hong…

2 hours ago

Bangladesh vs South Africa, Women’s T20 World Cup 2026: Proteas Survive Scare to Keep Semi-Final Hopes Alive

Key takeaways:South Africa beat Bangladesh in their Women's T20 World Cup 2026 match, with the…

2 hours ago

ENG vs IND 2026: England vs India Semi-Final — Dates, Venues and Live Coverage

Key takeaways:"ENG vs IND" is the standard cricket team-code pairing for England versus India; in…

3 hours ago